CAS NO: | 71125-38-7 |
规格: | ≥98% |
包装 | 价格(元) |
250mg | 电议 |
500mg | 电议 |
1g | 电议 |
2g | 电议 |
5g | 电议 |
10g | 电议 |
25g | 电议 |
Molecular Weight (MW) | 351.4 |
---|---|
Formula | C14H13N3O4S2 |
CAS No. | 71125-38-7 |
Storage | -20℃ for 3 years in powder form |
-80℃ for 2 years in solvent | |
Solubility (In vitro) | DMSO: 30 mg/mL (85.4 mM) |
Water:<1 mg/mL | |
Ethanol:<1 mg/mL | |
Other info | Chemical Name: (E)-3-(hydroxy((5-methylthiazol-2-yl)amino)methylene)-2-methyl-2H-benzo[e][1,2]thiazin-4(3H)-one 1,1-dioxide InChi Key: DWMREKMVXIFPFM-ACCUITESSA-N InChi Code: InChI=1S/C14H13N3O4S2/c1-8-7-15-14(22-8)16-13(19)11-12(18)9-5-3-4-6-10(9)23(20,21)17(11)2/h3-7,19H,1-2H3,(H,15,16)/b13-11+ SMILES: CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O |
Synonyms | Parocin; reumoxicam; Movicox; Mobic; Mobicox; Movalis; Meloxicamum; Uticox; |
In Vitro | In vitro activity: Meloxicam significantly reduces HCA-7 and Moser-S colony size. Meloxicam significantly inhibits HCA-7 colony and tumor growth but has no effect on the growth of the COX-2 negative HCT-116 cells. Meloxicam inhibits PGE(2) production, proliferation and invasiveness especially in MG-63 cells, which express relatively high levels of COX-2. Meloxicam causes apoptosis and upregulates Bax mRNA and protein in MG-63 cell culture. Cell Assay: CF41.Mg and MDCK cells are seeded at a density of 1.5 × 103 cells/well into 96-well plates, cultured for 24 h and then exposed to 0-25 μg/mL Meloxicam alone or in combination with doxorubicin. To evaluate synergism and sensitization, doxorubicin is added at the same time and after 24 h, respectively. MDCK cells are exposed only to Meloxicam as a non-tumor negative control. Control groups are cultured without Meloxicam and doxorubicin, but the corresponding amount of DMSO is added to the medium. Following an incubation period of 24 and 48 h, cell growth is measured using the MTS assay, with the absorbance at 490 nm determined using a microplate reader. Each experiment is performed 3 times in triplicate. |
---|---|
In Vivo | Meloxicam suppresses LM-8 tumor growth and lung metastasis in vivo mouse model. Meloxicam causes a significant reduction in lameness at post injection hour (PIH) 8 and 24 and tends to reduce effusion in horse. Meloxicam significantly suppresses synovial fluid (SF) prostaglandin E2 and substance P release at PIH 8 and bradykinin at PIH 24 compared to placebo treatment in horse. Meloxicam reduces general MMP activity at PIH 8 and 24 in horse. Meloxicam- or flunixin-treated horses has improved postoperative pain scores and clinical variables, compared with SS-treated horses. Meloxicam results in high numbers of neutrophils in ischemia-injured tissue of horse. Meloxicam administration significantly suppresses PGE2 concentrations in blood and synovial fluid at days 7 and 21, but has no effect on concentrations of TXB2 in blood or PGE2 in gastric mucosa in dogs. |
Animal model | Mice, horse, and dogs |
Formulation & Dosage | N/A |
References | Carcinogenesis. 1998 Dec;19(12):2195-9; Equine Vet J. 2009 Sep;41(7):693-9; Carcinogenesis. 2006 Mar;27(3):584-92; Am J Vet Res. 2007 Jun;68(6):614-24. |